Skip to content

ESD Home

TechCentury

Powered by

Engineering Society of Detroit Lawrence Technological University

Tag: Endocrine Diseases

Earnings / Pharmaceuticals

Loss grows at pharma startup Millendo

ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq:MLND), a clinical stage biopharmaceutical company developing novel treatments for endocrine diseases with significant unmet needs, reported a loss of $12 million or 65 cents per …

Pharmaceuticals / Startups

Millendo names chief commercial officer

ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), the developer of new endocrine drugs, announced the promotion of Thomas Hoover to the newly created position of chief commercial officer. Hoover joined Millendo …

Pharmaceuticals

Ann Arbor Pharma Firm Gets $62M To Commercialize Drug For Ovarian Disease

ANN ARBOR — Millendo Therapeutics Inc., the Ann Arbor pharma firm, announced an exclusive license agreement with the pharmaceutical giant AstraZeneca for the worldwide development and commercialization rights to AZD4901, …

Read the magazine:

TechCentury
Advertise or Contribute an Article
Lawrence Technological University

Subscribe to TechCentury.com

Top Posts

  • Saginaw Twp. requests residents to participate in broadband survey
  • Liquid Web Bought Out By Chicago Firm; Founding CEO To Step Down
  • LTU names unique research center after Engineering Dean Nabil Grace
  • LTU to lead foundation’s effort to boost engineering research with an entrepreneurial mindset
  • Urban Science awards $25,000 to ESD to create engineering career pathways for girls, diversify STEM fields

Archives

Follow Us On

© The Engineering Society of Detroit   |   ABOUT